DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

Not Applicable

Active, not recruiting

Conditions: Gynecologic Cancer

Interventions: Device: MRI
Radiation: Brachytherapy
Device: MRI Tracker

First Posted Date: 2017-09-11

Last Posted Date: 2024-10-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT03277469

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1

Terminated

Conditions: Metastatic Ovarian Cancer
Metastatic Vaginal Cancer
Recurrent Cervical Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Endometrial Cancer
Metastatic Vulvar Cancer
Metastatic Endometrial Cancer
Recurrent Gynecological Cancer
Metastatic Cervical Cancer
Recurrent Vaginal Cancer

Interventions: Drug: Durvalumab
Radiation: Radiation Therapy
Drug: Tremelimumab

First Posted Date: 2017-09-11

Last Posted Date: 2023-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT03277482

Locations: 🇺🇸
Martin King, Boston, Massachusetts, United States

Nivolumab Plus Ipilimumab in Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2017-08-11

Last Posted Date: 2024-06-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03246958

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Other: Standard Care
Other: Shared Care

First Posted Date: 2017-08-10

Last Posted Date: 2024-08-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 404

Registration Number: NCT03244826

Locations: 🇺🇸
Dana-Farber at South Shore Hospital, Weymouth, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Northern Light Cancer Center dba Eastern Maine Medical Center, Bangor, Maine, United States

and more 6 locations

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Pembrolizumab
Drug: Trebananib

First Posted Date: 2017-08-03

Last Posted Date: 2025-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03239145

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Smoldering Multiple Myeloma
Monoclonal Gammopathy

Interventions: Drug: Daratumumab

First Posted Date: 2017-08-01

Last Posted Date: 2025-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT03236428

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Post-Operative Ambulatory Challenge and Exercise (PACE) Trial

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Mobility Tracker

First Posted Date: 2017-08-01

Last Posted Date: 2020-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT03234933

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Nivolumab

First Posted Date: 2017-07-24

Last Posted Date: 2018-08-14

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT03227432

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Phase 1

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ulocuplumab
Drug: Ibrutinib

First Posted Date: 2017-07-21

Last Posted Date: 2024-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT03225716

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Phase 1

Recruiting

Conditions: Lymphocytic Leukemia

Interventions: Drug: NeoVax
Drug: Cyclophosphamide
Drug: Pembrolizumab

First Posted Date: 2017-07-17

Last Posted Date: 2025-05-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03219450

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy